When it comes to MRD, AML ≠ ALL

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Only the most specific main institutional affiliation is listed for Inside Blood authors, without indications of subdivisions, departments, parent institutions, or postal/geographic information. Please confirm or correct affiliation. Minimal residual disease (MRD) detection is standard of care in acute lymphoblastic leukemia (ALL), but not acute myeloid leukemia (AML). In this issue of Blood, anAML trial by Loken and colleagues from the Children's Oncology Group (COG) retrospectively demonstrates clinical significance of MRD. These data reaffirm that AML-MRDis unlike ALL-MRD.

Original languageEnglish (US)
Pages (from-to)1536-1537
Number of pages2
JournalBlood
Volume120
Issue number8
DOIs
StatePublished - Aug 23 2012

Fingerprint

Residual Neoplasm
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Acute Myeloid Leukemia
Blood
Oncology
Standard of Care

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

When it comes to MRD, AML ≠ ALL. / Paietta, Elisabeth M.

In: Blood, Vol. 120, No. 8, 23.08.2012, p. 1536-1537.

Research output: Contribution to journalArticle

Paietta, Elisabeth M. / When it comes to MRD, AML ≠ ALL. In: Blood. 2012 ; Vol. 120, No. 8. pp. 1536-1537.
@article{faf44b9867484c66b8b1135b8d6e2da2,
title = "When it comes to MRD, AML ≠ ALL",
abstract = "Only the most specific main institutional affiliation is listed for Inside Blood authors, without indications of subdivisions, departments, parent institutions, or postal/geographic information. Please confirm or correct affiliation. Minimal residual disease (MRD) detection is standard of care in acute lymphoblastic leukemia (ALL), but not acute myeloid leukemia (AML). In this issue of Blood, anAML trial by Loken and colleagues from the Children's Oncology Group (COG) retrospectively demonstrates clinical significance of MRD. These data reaffirm that AML-MRDis unlike ALL-MRD.",
author = "Paietta, {Elisabeth M.}",
year = "2012",
month = "8",
day = "23",
doi = "10.1182/blood-2012-06-435081",
language = "English (US)",
volume = "120",
pages = "1536--1537",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "8",

}

TY - JOUR

T1 - When it comes to MRD, AML ≠ ALL

AU - Paietta, Elisabeth M.

PY - 2012/8/23

Y1 - 2012/8/23

N2 - Only the most specific main institutional affiliation is listed for Inside Blood authors, without indications of subdivisions, departments, parent institutions, or postal/geographic information. Please confirm or correct affiliation. Minimal residual disease (MRD) detection is standard of care in acute lymphoblastic leukemia (ALL), but not acute myeloid leukemia (AML). In this issue of Blood, anAML trial by Loken and colleagues from the Children's Oncology Group (COG) retrospectively demonstrates clinical significance of MRD. These data reaffirm that AML-MRDis unlike ALL-MRD.

AB - Only the most specific main institutional affiliation is listed for Inside Blood authors, without indications of subdivisions, departments, parent institutions, or postal/geographic information. Please confirm or correct affiliation. Minimal residual disease (MRD) detection is standard of care in acute lymphoblastic leukemia (ALL), but not acute myeloid leukemia (AML). In this issue of Blood, anAML trial by Loken and colleagues from the Children's Oncology Group (COG) retrospectively demonstrates clinical significance of MRD. These data reaffirm that AML-MRDis unlike ALL-MRD.

UR - http://www.scopus.com/inward/record.url?scp=84865409622&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865409622&partnerID=8YFLogxK

U2 - 10.1182/blood-2012-06-435081

DO - 10.1182/blood-2012-06-435081

M3 - Article

C2 - 22918419

AN - SCOPUS:84865409622

VL - 120

SP - 1536

EP - 1537

JO - Blood

JF - Blood

SN - 0006-4971

IS - 8

ER -